Clinical trial
Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer
NCT00454324 · UNC Lineberger Comprehensive Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00454324 |
|---|---|
| Title | Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer |
| Official title | Phase II Clinical Trial of Carboplatin and Abraxane in Patients With Extensive Stage Small Cell Lung Cancer |
| Acronym | NRR |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Carboplatin, Abraxane |
| Enrollment | 30 |
| Start date | Apr 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | Dec 1, 2014 |
| First posted | Mar 30, 2007 |
| Last update posted | Jul 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: